Published in Ann Surg on March 01, 2008
Peritoneal carcinomatosis. World J Gastroenterol (2013) 1.04
Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC. Gastroenterol Res Pract (2012) 0.98
Indications and procedures for second-look surgery in acute mesenteric ischemia. Surg Today (2010) 0.94
Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int (2014) 0.93
Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. Int J Surg Oncol (2010) 0.93
Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int (2011) 0.92
Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol (2014) 0.91
Management of peritoneal carcinomatosis from colorectal cancer: review of the literature. Int J Colorectal Dis (2014) 0.85
Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach? Gastroenterol Res Pract (2012) 0.81
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: where are we? World J Gastroenterol (2012) 0.80
Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol (2016) 0.79
Current role of hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from colorectal cancer. World J Gastroenterol (2010) 0.79
Single-incision flexible endoscopy (SIFE) for detection and staging of peritoneal carcinomatosis. Surg Endosc (2015) 0.78
Risk factors for recurrence following complete cytoreductive surgery and HIPEC in colorectal cancer-derived peritoneal surface malignancies. Langenbecks Arch Surg (2013) 0.78
Colorectal cancer at high risk of peritoneal metastases: long term outcomes of a pilot study on adjuvant laparoscopic HIPEC and future perspectives. Oncotarget (2017) 0.78
Laparoscopic cytoreductive surgery and early postoperative intraperitoneal chemotherapy for patients with colorectal cancer peritoneal carcinomatosis: initial results from a single center. Surg Endosc (2013) 0.76
Clinical analysis of Krukenberg tumours in patients with colorectal cancer-a review of 57 cases. World J Surg Oncol (2017) 0.75
Patients at risk for peritoneal surface malignancy of colorectal cancer origin: the role of second look laparotomy. J Cancer (2013) 0.75
Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature. Gastroenterol Res Pract (2016) 0.75
Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol (2016) 0.75
Peritoneal Metastases: Prevention and Treatment. Indian J Surg Oncol (2016) 0.75
A feasibility study of the use of computed virtual chromoendoscopy for laparoscopic evaluation of peritoneal metastases. Surg Endosc (2016) 0.75
Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease? Tech Coloproctol (2013) 0.75
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol (2006) 7.05
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol (2011) 4.77
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res (2005) 3.44
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol (2008) 3.24
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol (2012) 2.92
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol (2012) 2.62
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol (2011) 2.26
Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol (2009) 2.26
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. Clin Breast Cancer (2010) 2.12
Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol (2003) 2.09
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res (2012) 2.04
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]. Gastroenterol Clin Biol (2002) 2.04
Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol (2005) 1.96
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res (2003) 1.92
Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol (2004) 1.81
Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol (2006) 1.76
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol (2010) 1.74
Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol (2004) 1.72
Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol (2012) 1.67
Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg (2015) 1.56
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery (2005) 1.51
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol (2002) 1.51
Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology (2010) 1.51
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer (2007) 1.51
Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. Gastroenterol Clin Biol (2007) 1.48
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology (2006) 1.45
Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology (2002) 1.44
BIRADS classification in mammography. Eur J Radiol (2006) 1.35
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer (2012) 1.32
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 1.30
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol (2002) 1.27
Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology (2005) 1.26
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol (2007) 1.23
Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol (2012) 1.21
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol (2007) 1.21
Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg (2013) 1.19
mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer (2011) 1.19
Malignant gastroduodenal obstruction: palliation with self-expanding metallic stents. J Vasc Interv Radiol (2005) 1.19
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol (2005) 1.18
Pancreatic metastases: a multicentric study of 22 patients. Gastroenterol Clin Biol (2004) 1.18
A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg (2010) 1.16
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab (2007) 1.16
New potential and applications of contrast-enhanced ultrasound of the breast: Own investigations and review of the literature. Eur J Radiol (2008) 1.12
Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. Eur J Radiol (2005) 1.11
Transanal endoscopic total mesorectal excision combined with single-port laparoscopy. Dis Colon Rectum (2012) 1.09
Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging (2007) 1.08
MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol (2003) 1.07
Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol (2005) 1.07
Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). Eur J Radiol (2008) 1.06